Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
HEPARIN SODIUM
PFIZER CANADA ULC
B01AB51
HEPARIN, COMBINATIONS
2UNIT
SOLUTION
HEPARIN SODIUM 2UNIT
INTRAVENOUS
500ML/1000ML
Ethical
HEPARINS
Active ingredient group (AIG) number: 0104596011; AHFS:
APPROVED
2017-06-13
PRESCRIBING INFORMATION HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION Heparin Sodium in 0.9% Sodium Chloride 2 USP Heparin Units/mL in Flexible Plastic (PVC) Containers Anticoagulant Pfizer Canada ULC 17300 Trans-Canada Highway Kirkland, Québec H9J 2M5 Date of Approval: March 8, 2019 Submission Control No: 222931 _______________________________________________________________________________ _ _Heparin Sodium in 0.9% Sodium Chloride Injection _ _ _ _Page 2 of 12 _ HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION 2 USP Heparin Units/mL in Flexible Plastic (PVC) Containers THERAPEUTIC CLASSIFICATION Anticoagulant ACTION AND CLINICAL PHARMACOLOGY Heparin inhibits reactions which lead to the clotting of blood and the formation of fibrin clots _in _ _vitro _and _in vivo_. Heparin acts at multiple sites in the normal coagulation system. Small amounts of heparin, in combination with antithrombin III (heparin cofactor), can inhibit thrombosis by inactivating activated Factor X, and preventing the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of heparin, in combination with antithrombin III, can inhibit further coagulation by inactivating thrombin and earlier clotting intermediates, thus preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Bleeding time is usually unaffected by heparin. Clotting time is usually not measurably affected by low doses, but is prolonged by full therapeutic doses of heparin. Heparin is only active parenterally. In doses less than 5 000 units, heparin is primarily eliminated by hepatic metabolism. In larger doses, up to 50% is excreted unchanged in the urine. The plasma half-life is approximately 1.5 hours; however, the half-life increases with increasing doses, ranging from approximately 1 hour with a dose of 100 units/kg to approximately 2.5 hours with a dose of 400 units/kg. The plasma half-life may be prolonged in patients wi Prečítajte si celý dokument